To assist the regulatory assessment of serological tests for Zika virus, the FDA has provided manufacturers with a panel of human plasma samples, according to a release issued by the organization.

“At the onset of the Zika virus outbreak, when little was known about the disease or how to diagnose it, the FDA worked quickly with manufacturers to encourage the development of diagnostic tests and ensure they were available using its Emergency Use Authorization authorities,” FDA Commissioner Scott Gottlieb, MD, said in the release.